Animal vaccines based on orally presented yeast recombinants

Vaccine

Volumn 31, Issue 40, 2013, Pages 4287-4292

  Shin, Min Kyoung ^a   Yoo, Han Sang ^a  

^a Seoul National University   (South Korea)

Author keywords

Live delivery system; Oral immunization; Veterinary vaccines; Yeast

Indexed keywords

GLYCOPROTEIN E2; HEMOLYSIN; LIVE VACCINE; MEMBRANE ANTIGEN; NEUTRALIZING ANTIBODY; PROBIOTIC AGENT; RECOMBINANT VACCINE; VIRUS CAPSID ANTIGEN; VIRUS PROTEIN;

ACTINOBACILLUS PLEUROPNEUMONIAE; BACTERIUM CARRIER; CANDIDA; CHICKEN; CLASSICAL SWINE FEVER; DRUG DELIVERY SYSTEM; ESCHERICHIA COLI; FERMENTATION; GENE EXPRESSION; GENE EXPRESSION SYSTEM; HEPATITIS B VIRUS; HETEROLOGOUS EXPRESSION; IMMUNE RESPONSE; IMMUNIZATION; INFECTION; INFECTIOUS BURSAL DISEASE VIRUS; INJECTION SITE PAIN; KLUYVEROMYCES LACTIS; MARINE SPECIES; METHYLOTROPHIC YEAST; MOLECULAR GENETICS; NONHUMAN; ORAL DRUG ADMINISTRATION; PICHIA ANGUSTA; PICHIA PASTORIS; PORCINE EPIDEMIC DIARRHEA VIRUS; PRIORITY JOURNAL; PROTEIN PROCESSING; REVIEW; SACCHAROMYCES BOULARDII; SACCHAROMYCES CEREVISIAE; SALMONELLA; SALMONID; SCHIZOSACCHAROMYCES POMBE; SHIGELLA; SWINE; VACCINATION; VETERINARY MEDICINE; VIBRIO HARVEYI; VIRAL CONTAMINATION; YARROWIA LIPOLYTICA; YEAST;

LIVE DELIVERY SYSTEM; ORAL IMMUNIZATION; VETERINARY VACCINES; YEAST;

ADMINISTRATION, ORAL; ANIMALS; ANTIGENS; DRUG DELIVERY SYSTEMS; GENE EXPRESSION; PROBIOTICS; VACCINATION; VACCINES; YEASTS;

EID: 84882924379     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2013.07.029     Document Type: Review

References (81)

1. Pastoret P.P. Veterinary vaccinology. Comptes Rendus De L Academie Des Sciences Serie III-Sciences De La Vie-Life Sciences 1999, 322(November (11)):967-972.
2. Shams H. Recent developments in veterinary vaccinology. Veterinary Journal 2005, 170(November (3)):289-299.
3. Shin M.K., Kang M.L., Jung M.H., Cha S.B., Lee W.J., Kim J.M., et al. Induction of protective immune responses against challenge of Actinobacillus pleuropneumoniae by oral administration with Saccharomyces cerevisiae expressing Apx toxins in pigs. Veterinary Immunology and Immunopathology 2013, 151(January (1/2)):132-139.
4. Gerdts V., Mutwiri G.K., Tikoo S.K., Babiuk L.A. Mucosal delivery of vaccines in domestic animals. Veterinary Research 2006, 37(May-June (3)):487-510.
5. Giudice E.L., Campbell J.D. Needle-free vaccine delivery. Advanced Drug Delivery Reviews 2006, 58(April (1)):68-89.
6. Pouwels P.H., Leer R.J., Shaw M., Heijne den Bak-Glashouwer M.J., Tielen F.D., Smit E., et al. Lactic acid bacteria as antigen delivery vehicles for oral immunization purposes. International Journal of Food Microbiology 1998, 41(May (2)):155-167.
7. Medina E., Guzman C.A. Use of live bacterial vaccine vectors for antigen delivery: potential and limitations. Vaccine 2001, 19(February (13/14)):1573-1580.
8. Larhed A., Stertman L., Edvardsson E., Sjoholm I. Starch microparticles as oral vaccine adjuvant: antigen-dependent uptake in mouse intestinal mucosa. Journal of Drug Targeting 2004, 12(June (5)):289-296.
9. Neutra M.R., Kozlowski P.A. Mucosal vaccines: the promise and the challenge. Nature Reviews Immunology 2006, 6(February (2)):148-158.
10. Hutchings A.B., Helander A., Silvey K.J., Chandran K., Lucas W.T., Nibert M.L., et al. Secretory immunoglobulin A antibodies against the sigma1 outer capsid protein of reovirus type 1 Lang prevent infection of mouse Peyer's patches. Journal of Virology 2004, 78(January (2)):947-957.
11. Cuburu N., Kweon M.N., Song J.H., Hervouet C., Luci C., Sun J.B., et al. Sublingual immunization induces broad-based systemic and mucosal immune responses in mice. Vaccine 2007, 25(December 51):8598-8610.
12. Quiding M., Nordstrom I., Kilander A., Andersson G., Hanson L.A., Holmgren J., et al. Intestinal immune responses in humans. Oral cholera vaccination induces strong intestinal antibody responses and interferon-gamma production and evokes local immunological memory. Journal of Clinical Investigation 1991, 88(July (1)):143-148.
13. van Ginkel F.W., Jackson R.J., Yuki Y., McGhee J.R. Cutting edge: the mucosal adjuvant cholera toxin redirects vaccine proteins into olfactory tissues. Journal of Immunology 2000, 165(November (9)):4778-4782.
14. Czerkinsky C., Holmgren J. Enteric vaccines for the developing world: a challenge for mucosal immunology. Mucosal Immunology 2009, 2(July (4)):284-287.
15. Azizi A., Kumar A., Diaz-Mitoma F., Mestecky J. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathogens 2010, 6(11):e1001147.
16. Streatfield S.J., Howard J.A. Plant-based vaccines. International Journal for Parasitology 2003, 33(May (5/6)):479-493.
17. Kotton C.N., Hohmann E.L. Enteric pathogens as vaccine vectors for foreign antigen delivery. Infection and Immunity 2004, 72(October (10)):5535-5547.
18. Shin S.J., Bae J.L., Cho Y.W., Lee D.Y., Kim D.H., Yang M.S., et al. Induction of antigen-specific immune responses by oral vaccination with Saccharomyces cerevisiae expressing Actinobacillus pleuropneumoniae ApxIIA. FEMS Immunology and Medical Microbiology 2005, 43(February (2)):155-164.
19. Kulkarni R.R., Parreira V.R., Jiang Y.F., Prescott J.F. A live oral recombinant Salmonella enterica serovar typhimurium vaccine expressing Clostridium perfringens antigens confers protection against necrotic enteritis in broiler chickens. Clinical and Vaccine Immunology 2010, 17(February (2)):205-214.
20. Scheppler L., Vogel M., Zuercher A.W., Zuercher M., Germond J.E., Miescher S.M., et al. Recombinant Lactobacillus johnsonii as a mucosal vaccine delivery vehicle. Vaccine 2002, 20(July (23/24)):2913-2920.
21. Hansson M., Nygren P.A., Stahl S. Design and production of recombinant subunit vaccines. Biotechnology and Applied Biochemistry 2000, 32(October (Pt 2)):95-107.
22. Walker G.M. Yeast physiology and biotechnology 1998, J. Wiley & Sons, Chichester, New York.
23. Park S.M., Mo A.Y., Lim J.G., Chung H.J., Kim T.G., Kim K.J., et al. Surface displayed expression of a neutralizing epitope of spike protein from a Korean strain of porcine epidemic diarrhea virus. Biotechnology and Bioprocess Engineering 2007, 12(November-December (6)):690-695.
24. Cino J. High-yield protein production from Pichia pastoris yeast: a protocol for benchtop fermentation. American Biotechnology Laboratory 1999, 17(6):10-21.
25. Akada R. Genetically modified industrial yeast ready for application. Journal of Bioscience and Bioengineering 2002, 94(6):536-544.
26. Stubbs A.C., Martin K.S., Coeshott C., Skaates S.V., Kuritzkes D.R., Bellgrau D., et al. Whole recombinant yeast vaccine activates dendritic cells and elicits protective cell-mediated immunity. Nature Medicine 2001, 7(May (5)):625-629.
27. Gellissen G., Hollenberg C.P. Application of yeasts in gene expression studies: a comparison of Saccharomyces cerevisiae, Hansenula polymorpha and Kluyveromyces lactis - a review. Gene 1997, 190(April (1)):87-97.
28. van Ooyen A.J., Dekker P., Huang M., Olsthoorn M.M., Jacobs D.I., Colussi P.A., et al. Heterologous protein production in the yeast Kluyveromyces lactis. FEMS Yeast Research 2006, 6(May (3)):381-392.
29. Gellissen G., Melber K., Janowicz Z.A., Dahlems U.M., Weydemann U., Piontek M., et al. Heterologous protein production in yeast. Antonie Van Leeuwenhoek 1992, 62(August (1/2)):79-93.
30. Gellissen G., Weydemann U., Strasser A.W., Piontek M., Janowicz Z.A., Hollenberg C.P. Progress in developing methylotrophic yeasts as expression systems. Trends in Biotechnology 1992, 10(December (12)):413-417.
31. Rose A.H., Harrison J.S. The yeasts 1987, Academic Press, London/San Diego. 2nd ed.
32. Strathern J.N., Jones E.W., Broach J.R. The molecular biology of the yeast Saccharomyces: metabolism and gene expression 1982, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
33. Broach J.R., Pringle J.R., Jones E.W. The molecular and cellular biology of the yeast Saccharomyces 1991, Cole Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.
34. Valenzuela P., Medina A., Rutter W.J., Ammerer G., Hall B.D. Synthesis and assembly of hepatitis B virus surface antigen particles in yeast. Nature 1982, 298(July (5872)):347-350.
35. Cregg J.M., Tschopp J.F., Stillman C., Siegel R., Akong M., Craig W.S., et al. High-level expression and efficient assembly of hepatitis-B surface-antigen in the methylotrophic yeast, Pichia-Pastoris. Nature Biotechnology 1987, 5(May (5)):479-485.
36. Lin G.J., Liu T.Y., Tseng Y.Y., Chen Z.W., You C.C., Hsuan S.L., et al. Yeast-expressed classical swine fever virus glycoprotein E2 induces a protective immune response. Veterinary Microbiology 2009, 139(November (3/4)):369-374.
37. Romanos M.A., Scorer C.A., Clare J.J. Foreign gene-expression in yeast - a review. Yeast 1992, 8(June (6)):423-488.
38. Arnold M., Durairaj V., Mundt E., Schulze K., Breunig K.D., Behrens S.E. Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit. PLoS ONE 2012, 7(9):e42870.
39. van den Berg J.A., van der Laken K.J., van Ooyen A.J., Renniers T.C., Rietveld K., Schaap A., et al. Kluyveromyces as a host for heterologous gene expression: expression and secretion of prochymosin. Bio/Technology (Nature Publishing Company) 1990, 8(February (2)):135-139.
40. Schreuder M.P., Brekelmans S., van den Ende H., Klis F.M. Targeting of a heterologous protein to the cell wall of Saccharomyces cerevisiae. Yeast 1993, 9(April (4)):399-409.
41. Schreuder M.P., Mooren A.T., Toschka H.Y., Verrips C.T., Klis F.M. Immobilizing proteins on the surface of yeast cells. Trends in Biotechnology 1996, 14(April (4)):115-120.
42. Murai T., Ueda M., Yamamura M., Atomi H., Shibasaki Y., Kamasawa N., et al. Construction of a starch-utilizing yeast by cell surface engineering. Applied and Environment Microbiology 1997, 63(April (4)):1362-1366.
43. Ueda M., Tanaka A. Genetic immobilization of proteins on the yeast cell surface. Biotechnology Advances 2000, 18(April (2)):121-140.
44. Kim J.M., Jung D.I., Eom Y.J., Park S.M., Yoo H.S., Jang Y.S., et al. Surface-displayed expression of a neutralizing epitope of ApxIIA exotoxin in Saccharomyces cerevisiae and oral administration of it for protective immune responses against challenge by Actinobacillus pleuropneumoniae. Bioscience, Biotechnology, and Biochemistry 2010, 74(7):1362-1367.
45. Schreuder M.P., Deen C., Boersma W.J., Pouwels P.H., Klis F.M. Yeast expressing hepatitis B virus surface antigen determinants on its surface: implications for a possible oral vaccine. Vaccine 1996, 14(April (5)):383-388.
46. Ueda M., Tanaka A. Cell surface engineering of yeast: construction of arming yeast with biocatalyst. Journal of Bioscience and Bioengineering 2000, 90(August (2)):125-136.
47. McFarland L.V. Systematic review and meta-analysis of Saccharomyces boulardii in adult patients. World Journal of Gastroenterology 2010, 16(May (18)):2202-2222.
48. Kelesidis T., Pothoulakis C. Efficacy and safety of the probiotic Saccharomyces boulardii for the prevention and therapy of gastrointestinal disorders. Therapeutic Advances in Gastroenterology 2012, 5(March (2)):111-125.
49. Sindhu S.C., Khetarpaul N. Effect of probiotic fermentation on antinutrients and in vitro protein and starch digestibilities of indigenously developed RWGT food mixture. Nutrition and Health 2002, 16(3):173-181.
50. Lourens-Hattingh A., Viljoen B.C. Growth and survival of a probiotic yeast in dairy products. Food Research International 2001, 34(9):791-796.
51. Czerucka D., Piche T., Rampal P. Review article: yeast as probiotics - Saccharomyces boulardii. Alimentary Pharmacology and Therapeutics 2007, 26(September (6)):767-778.
52. Dey S., Upadhyay C., Madhan Mohan C., Kataria J.M., Vakharia V.N. Formation of subviral particles of the capsid protein VP2 of infectious bursal disease virus and its application in serological diagnosis. Journal of Virological Methods 2009, 157(April (1)):84-89.
53. Pitcovski J., Gutter B., Gallili G., Goldway M., Perelman B., Gross G., et al. Development and large-scale use of recombinant VP2 vaccine for the prevention of infectious bursal disease of chickens. Vaccine 2003, 21(December (32)):4736-4743.
54. Macreadie I.G., Vaughan P.R., Chapman A.J., McKern N.M., Jagadish M.N., Heine H.G., et al. Passive protection against infectious bursal disease virus by viral VP2 expressed in yeast. Vaccine 1990, 8(December (6)):549-552.
55. Villegas P., Hamoud M., Purvis L.B., Perozo F. Infectious bursal disease subunit vaccination. Avian Diseases 2008, 52(December (4)):670-674.
56. Allnutt F.C., Bowers R.M., Rowe C.G., Vakharia V.N., LaPatra S.E., Dhar A.K. Antigenicity of infectious pancreatic necrosis virus VP2 subviral particles expressed in yeast. Vaccine 2007, 25(June (26)):4880-4888.
57. Shin S.J., Bae J.L., Cho Y.W., Yang M.S., Kim D.H., Jang Y.S., et al. Expression of apxIA of Actinobacillus pleuropneumoniae in Saccharomyces cerevisiae. Journal of Veterinary Science 2003, 4(December (3)):225-228.
58. Shin S.J., Shin S.W., Choi E.J., Lee D.Y., Ahn J.M., Yang M.S., et al. A predictive model for the level of sIgA based on IgG levels following the oral administration of antigens expressed in Saccharomyces cerevisiae. Journal of Veterinary Science 2005, 6(December (4)):305-309.
59. Shin S.J., Shin S.W., Kang M.L., Lee D.Y., Yang M.S., Jang Y.S., et al. Enhancement of protective immune responses by oral vaccination with Saccharomyces cerevisiae expressing recombinant Actinobacillus pleuropneumoniae ApxIA or ApxIIA in mice. Journal of Veterinary Science 2007, 8(December (4)):383-392.
60. Shin M.K., Lee W.J., Jung M.H., Cha S.B., Shin S.W., Yoo A., et al. Oral immunization of mice with Saccharomyces cerevisiae expressing a neutralizing epitope of ApxIIA exotoxin from Actinobacillus pleuropneumoniae induces systemic and mucosal immune responses. Microbiology and Immunology 2013, 57(June (6)):417-425.
61. Zhu K., Chi Z., Li J., Zhang F., Li M., Yasoda H.N., et al. The surface display of haemolysin from Vibrio harveyi on yeast cells and their potential applications as live vaccine in marine fish. Vaccine 2006, 24(August (35/36)):6046-6052.
62. Gurkan C., Ellar D.J. Recombinant production of bacterial toxins and their derivatives in the methylotrophic yeast Pichia pastoris. Microbial Cell Factories 2005, December (4):1-8.
63. Schellenberg D., Bonington A., Champion C.M., Lancaster R., Webb S., Main J. Treatment of Clostridium-Difficile diarrhea with Brewers-yeast. Lancet 1994, 343(January (8890)):171-172.
64. Buts J.P., Corthier G., Delmee M. Saccharomyces boulardii for Clostridium difficile-associated enteropathies in infants. Journal of Pediatric Gastroenterology and Nutrition 1993, 16(May (4)):419-425.
65. Born P., Lersch C., Zimmerhackl B., Classen M. The Saccharomyces boulardii therapy of HIV-associated diarrhea. Deutsche Medizinische Wochenschrift 1993, 118(May (20)):765.
66. Plein K., Hotz J. Therapeutic effects of Saccharomyces boulardii on mild residual symptoms in a stable phase of Crohn's disease with special respect to chronic diarrhea - a pilot study. Zeitschrift fur Gastroenterologie 1993, 31(February (2)):129-134.
67. McFarland L.V. Can Saccharomyces boulardii prevent antibiotic-associated diarrhea in children?. Nature Clinical Practice Gastroenterology & Hepatology 2005, 2(June (6)):262-263.
68. Corthier G., Lucas F., Jouvert S., Castex F. Effect of oral Saccharomyces boulardii treatment on the activity of Clostridium difficile toxins in mouse digestive tract. Toxicon 1992, 30(December (12)):1583-1589.
69. Berg R., Bernasconi P., Fowler D., Gautreaux M. Inhibition of Candida albicans translocation from the gastrointestinal tract of mice by oral administration of Saccharomyces boulardii. Journal of Infectious Diseases 1993, 168(November (5)):1314-1318.
70. Capilla J., Clemons K.V., Liu M., Levine H.B., Stevens D.A. Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 2009, 27(June (27)):3662-3668.
71. Collier C.T., Carroll J.A., Ballou M.A., Starkey J.D., Sparks J.C. Oral administration of Saccharomyces cerevisiae boulardii reduces mortality associated with immune and cortisol responses to Escherichia coli endotoxin in pigs. Journal of Animal Science 2011, 89(January (1)):52-58.
72. Fattal-German M., Bizzini B. Assessment of the anti-viral effect of a short-term oral treatment of mice with live Saccharomyces cerevisiae cells. Developments in Biological Standardization 1992, 77:115-120.
73. Jung K., Ha Y., Ha S.K., Han D.U., Kim D.W., Moon W.K., et al. Antiviral effect of Saccharomyces cerevisiae beta-glucan to swine influenza virus by increased production of interferon-gamma and nitric oxide. Journal of Veterinary Medicine. B, Infectious Diseases and Veterinary Public Health 2004, 51(March (2)):72-76.
74. Ortuno J., Cuesta A., Rodriguez A., Esteban M.A., Meseguer J. Oral administration of yeast. Saccharomyces cerevisiae, enhances the cellular innate immune response of gilthead seabream (Sparus aurata L.). Veterinary Immunology and Immunopathology 2002, 85(February (1/2)):41-50.
75. Riemann H., Takao J., Shellman Y.G., Hines W.A., Edwards C.K., Franzusoff A., et al. Generation of a prophylactic melanoma vaccine using whole recombinant yeast expressing MART-1. Experimental Dermatology 2007, 16(October (10)):814-822.
76. Lu Y., Bellgrau D., Dwyer-Nield L.D., Malkinson A.M., Duke R.C., Rodell T.C., et al. Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Research 2004, 64(August (15)):5084-5088.
77. Franzusoff A., Duke R.C., King T.H., Lu Y., Rodell T.C. Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opinion on Biological Therapy 2005, 5(April (4)):565-575.
78. Tanaka A., Jensen J.D., Prado R., Riemann H., Shellman Y.G., Norris D.A., et al. Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Therapy 2011, 18(August (8)):827-834.
79. Wansley E.K., Chakraborty M., Hance K.W., Bernstein M.B., Boehm A.L., Guo Z., et al. Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses. Clinical Cancer Research 2008, 14(July (13)):4316-4325.
80. Haller A.A., Lauer G.M., King T.H., Kemmler C., Fiolkoski V., Lu Y., et al. Whole recombinant yeast-based immunotherapy induces potent T cell responses targeting HCV NS3 and Core proteins. Vaccine 2007, 25(February (8)):1452-1463.
81. Barron M.A., Blyveis N., Pan S.C., Wilson C.C. Human dendritic cell interactions with whole recombinant yeast: implications for HIV-1 vaccine development. Journal of Clinical Immunology 2006, 26(May (3)):251-264.